Literature DB >> 24809686

Characteristics and occurrence of speech impairment in Huntington's disease: possible influence of antipsychotic medication.

Jan Rusz1, Jiří Klempíř, Tereza Tykalová, Eva Baborová, Roman Čmejla, Evžen Růžička, Jan Roth.   

Abstract

Although motor speech impairment is a common manifestation of Huntington's disease (HD), its description remains limited. The aim of the current study was therefore to estimate the occurrence and characteristics of speech disorder in HD and to explore the influence of antipsychotic medication on speech performance. Speech samples, including reading passage and monologue, were acquired from 40 individuals diagnosed with HD and 40 age- and sex-matched healthy controls. Objective acoustic analyses were used to evaluate key aspects of speech including vowel articulation, intensity, pitch and timing. A predictive model was constructed to detect the occurrence and most prominent patterns of speech dysfunction in HD. We revealed that 93% of HD patients manifest some degree of speech impairment. Decreased number of pauses, slower articulation rate, imprecise vowel articulation and excess intensity variations were found to be the most salient patterns of speech dysfunction in HD. We further demonstrated that antipsychotic medication may induce excessive loudness and pitch variations perceptually resembling excess patterns of word stress, and may also accentuate general problems with speech timing. Additionally, antipsychotics induced a slight improvement of vowel articulation. Specific speech alterations observed in HD patients indicate that speech production may reflect the pathophysiology of the disease as well as treatment effects, and may therefore be considered a valuable marker of functional disability in HD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24809686     DOI: 10.1007/s00702-014-1229-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  31 in total

1.  Impaired motor speech performance in Huntington's disease.

Authors:  Sabine Skodda; Uwe Schlegel; Rainer Hoffmann; Carsten Saft
Journal:  J Neural Transm (Vienna)       Date:  2013-11-13       Impact factor: 3.575

2.  Variation of selective gray and white matter atrophy in Huntington's disease.

Authors:  Robert Jech; Jirí Klempír; Josef Vymazal; Jana Zidovská; Olga Klempírová; Evzen Růzicka; Jan Roth
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

3.  Comprehension of complex discourse in different stages of Huntington's disease.

Authors:  Charlotta Saldert; Angelika Fors; Sofia Ströberg; Lena Hartelius
Journal:  Int J Lang Commun Disord       Date:  2010 Nov-Dec       Impact factor: 3.020

4.  Quantifying speech rhythm abnormalities in the dysarthrias.

Authors:  Julie M Liss; Laurence White; Sven L Mattys; Kaitlin Lansford; Andrew J Lotto; Stephanie M Spitzer; John N Caviness
Journal:  J Speech Lang Hear Res       Date:  2009-08-28       Impact factor: 2.297

5.  Erythromycin-induced clozapine toxic reaction.

Authors:  L G Cohen; S Chesley; L Eugenio; J G Flood; J Fisch; D C Goff
Journal:  Arch Intern Med       Date:  1996-03-25

6.  Speech acoustic markers of early stage and prodromal Huntington's disease: a marker of disease onset?

Authors:  Adam P Vogel; Christopher Shirbin; Andrew J Churchyard; Julie C Stout
Journal:  Neuropsychologia       Date:  2012-09-14       Impact factor: 3.139

7.  Oral diadochokinesis in neurological dysarthrias.

Authors:  H Ackermann; I Hertrich; T Hehr
Journal:  Folia Phoniatr Logop       Date:  1995       Impact factor: 0.849

Review 8.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

9.  Impairment of vowel articulation as a possible marker of disease progression in Parkinson's disease.

Authors:  Sabine Skodda; Wenke Grönheit; Uwe Schlegel
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

10.  Objective acoustic quantification of phonatory dysfunction in Huntington's disease.

Authors:  Jan Rusz; Jiří Klempíř; Eva Baborová; Tereza Tykalová; Veronika Majerová; Roman Cmejla; Evžen Růžička; Jan Roth
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

View more
  10 in total

1.  Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.

Authors:  Jan Rusz; Cecilia Bonnet; Jiří Klempíř; Tereza Tykalová; Eva Baborová; Michal Novotný; Aaron Rulseh; Evžen Růžička
Journal:  J Neurol       Date:  2015-02-17       Impact factor: 4.849

2.  Motor speech patterns in Huntington disease.

Authors:  Sarah K Diehl; Antje S Mefferd; Ya-Chen Lin; Jessie Sellers; Katherine E McDonell; Michael de Riesthal; Daniel O Claassen
Journal:  Neurology       Date:  2019-10-29       Impact factor: 9.910

3.  Phonatory dysfunction as a preclinical symptom of Huntington disease.

Authors:  Jan Rusz; Carsten Saft; Uwe Schlegel; Rainer Hoffman; Sabine Skodda
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

4.  Hypernasality associated with basal ganglia dysfunction: evidence from Parkinson's disease and Huntington's disease.

Authors:  Michal Novotný; Jan Rusz; Roman Čmejla; Hana Růžičková; Jiří Klempíř; Evžen Růžička
Journal:  PeerJ       Date:  2016-09-29       Impact factor: 2.984

Review 5.  Speech-Language Pathology Evaluation and Management of Hyperkinetic Disorders Affecting Speech and Swallowing Function.

Authors:  Julie M Barkmeier-Kraemer; Heather M Clark
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-09-21

6.  A Systematic Review of Rehabilitation for Corticobulbar Symptoms in Adults with Huntington's Disease.

Authors:  Emma Burnip; Emma Wallace; Kristin Gozdzikowska; Maggie-Lee Huckabee
Journal:  J Huntingtons Dis       Date:  2020

7.  Dysarthria Subgroups in Talkers with Huntington's Disease: Comparison of Two Data-Driven Classification Approaches.

Authors:  Daniel Kim; Sarah Diehl; Michael de Riesthal; Kris Tjaden; Stephen M Wilson; Daniel O Claassen; Antje S Mefferd
Journal:  Brain Sci       Date:  2022-04-13

8.  Using a Clinical Formulation to Understand Psychological Distress in People Affected by Huntington's Disease: A Descriptive, Evidence-Based Model.

Authors:  Maria Dale; Ashleigh Wood; Nicolò Zarotti; Fiona Eccles; Sarah Gunn; Reza Kiani; Amanda Mobley; Noelle Robertson; Jane Simpson
Journal:  J Pers Med       Date:  2022-07-27

9.  Predicting clinical scores in Huntington's disease: a lightweight speech test.

Authors:  Rachid Riad; Marine Lunven; Hadrien Titeux; Xuan-Nga Cao; Jennifer Hamet Bagnou; Laurie Lemoine; Justine Montillot; Agnes Sliwinski; Katia Youssov; Laurent Cleret de Langavant; Emmanuel Dupoux; Anne-Catherine Bachoud-Lévi
Journal:  J Neurol       Date:  2022-05-14       Impact factor: 6.682

10.  Automatic Evaluation of Speech Rhythm Instability and Acceleration in Dysarthrias Associated with Basal Ganglia Dysfunction.

Authors:  Jan Rusz; Jan Hlavnička; Roman Čmejla; Evžen Růžička
Journal:  Front Bioeng Biotechnol       Date:  2015-07-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.